Despite the development of new diagnostic tests, new antimicrobial agents, and the implementation of international guidelines in recent decades, community-acquired pneumonia still has high morbidity and mortality worldwide and is associated with moderate health costs. Streptococcus pneumoniae is still the most frequent pathogen related to microbial aetiology of community-acquired pneumonia, although almost 50% of cases of pneumonia still have no microbiological diagnosis. However, the development of molecular techniques such as real-time polymerase chain reaction in the past five years has revealed respiratory viruses to be major causative agents in community-acquired pneumonia. With the explosion of information from the many studies focusing on community-acquired pneumonia epidemiology, microbial aetiology and management in the last 15 years, the introduction of predictive tools, and advances in the pathophysiology of the disease, management of community-acquired pneumonia has also improved over this time due to the implementation of international guidelines proposed by different scientific associations. This review focuses on the new data in the management of community-acquired pneumonia. (BRN Rev. 2016;2:253-73)
INTRODUCTION
Despite the development of new diagnostic tests, new antimicrobial agents, and the implementation of international guidelines in recent decades, community-acquired pneumonia (CAP) still has high morbidity and mortality worldwide and is associated with moderate health costs 1 .
There is consistent evidence that the incidence of CAP has risen in recent decades and the hospitalization rate has increased. However, there is no concrete explanation for this phenomenon 2 . It is true that mortality related to CAP has declined over time in the general population 3 . However, in patients with severe CAP, mortality rates remain as high as 35% in cases requiring admission to an intensive care unit (ICU) 4 .
Streptococcus pneumoniae (pneumococcus) remains the most frequent pathogen in CAP in all settings (outpatients, patients requiring hospitalization, and patients requiring ICU treatment), in all age groups, and regardless of comorbidity 5 . The improvement of molecular diagnostic techniques in the last years has demonstrated the increasing prevalence of respiratory viruses in CAP 6 . The Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak, the severe acute respiratory syndrome coronavirus (SARS-CoV) epidemic, and the 2009 H1N1 influenza pandemic are some examples of new viral pathogens involved in pneumonia 7 .
Another important difficulty related to the management of CAP patients is the considerable problem with the emergence of antimicrobial resistance of common pathogens in CAP, especially multidrug-resistant pneumococcal clones and gram-negative bacilli.
Moreover, we know that the increased use of antibiotics generates resistance in microorganisms through adaptation to antibiotic pressure. Between 2000 and 2010, global antibiotic use increased by 36% from approximately 50 to 70 billion standard units, based on data from 71 countries, including most countries with large populations 8 (Fig. 1 ).
This review focuses on the data published from 2000 to 2015 on the more important aspects of CAP.
EPIDEMIOLOGY OF COMMUNITY-ACQUIRED PNEUMONIA
World Health Organization (WHO) 2012 statistics indicate that lower respiratory tract infections (LRTI) are the fourth cause of death globally and the number one cause of death in low-income countries 9 . In the USA, pneumonia was reported as the ninth most common cause of death in 2010 10 . In 2013, The Global Burden of Disease Study reported that LRTI are the second cause of death; this report was based on data from 188 countries around the world 11 . In Europe, mortality rates for CAP vary widely from country to country, ranging from < 1 to 48% 1 .
In a comprehensive literature review, Torres et al. 12 found the overall annual incidence of CAP in Europe to be between 1.07 and 1.2 per 1000 person-years and 1.54 and 1.7 per 1000 population. In the same review, the authors found that the incidence of CAP increased with age to 14 per 1000 person-years in adults aged ≥ 65 years and the incidence of CAP was significantly higher in men than in women 12 (Fig. 2) .
The Etiology of Pneumonia in the Community (EPIC) study reported by Jain et al. 6 found an increased incidence of pneumonia with increasing age; the annual incidence of pneumonia in the US was 24.8 cases per 10,000 adults, with the highest rates among adults 65-79 years of age (63.0 cases per 10,000 adults) and those 80 years of age or older (164.3 cases per 10,000 adults).
The economic cost related to CAP remains high. A recently published Dutch study that included 195,372 CAP cases reported that the median costs of CAP case were dependent on age and type of care, with costs ranging from €344 (€482) per episode for 0-9 year olds treated as outpatients, to €10,284 (€16,374) per episode for 50-64 year olds admitted to the ICU 13 . Another major study that provides an overview of the importance of comorbidity conditions in the economic cost of pneumonia (Fig. 3) is the recently published study by Weycker et al. 14 on the rates and cost of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions.
Despite the implementation of important measures in recent decades, such as widespread 
TREATMENT TRENDS
The first comprehensive, global report on antibiotic use shows that the drugs are increasingly popular in low-and middle-income countries. 
RISK FACTORS
In the past 15 years, several studies have reported specific risk factors for CAP 15, 16 .
Age
Pneumonia can occur at any age, but its incidence increases significantly with advanced age. The EPIC study reported by Jain et al. 6 found an increased incidence of pneumonia with increasing age; the annual incidence of pneumonia was 24.8 cases per 10,000 adults, with the highest rates among adults aged between 65 and 79 years (63.0 cases per 10,000 adults) and those aged 80 years or older (164.3 cases per 10,000 adults). Viral pneumonia is most frequent in middle-aged adults 17 . However, the incidence is variable in immunocompetent adults and increases with epidemics and ageing 18 .
Male sex
A recently published article by Li et al. 19 suggested that being male is an increased risk for increase hospital mortality in patients admitted to the ICU with pneumonia.
Lifestyle factors and risk of community-acquired pneumonia
Several case-control studies have demonstrated the association between lifestyle factors and the risk of CAP 15 .
-Exposure to cigarette smoke was associated with an increased risk of CAP. Smoking is associated with colonization by pathogenic bacteria and an increased risk of lung infections, especially in the case of S. pneumoniae 20 .
-Higher consumption of alcohol (≥ 80 g/l) is a risk factor for CAP. Samokhvalo et al. 21 performed a meta-analysis that showed that the consumption of 24, 60, and 120 g of pure alcohol daily resulted in a relative risk for CAP incidents of 1.12 (95% CI: 1.02-1.23), 1.33 (95% CI: 1.06-1.67), and 1.76 (95% CI: 1.13-2.77), respectively, relative to non-drinkers.
-Being underweight is associated with increased risk of CAP, so it is reported that obese patients with pneumonia have lower mortality compared to normal weight patients 12 .
-Living conditions: living in a household of more than 10 people, regular contact with children, higher levels of education, and good dental hygiene were associated with reduced risk of CAP 12, 16 .
Specific comorbidities and risk of community-acquired pneumonia 23, 24 . However, despite the risk of CAP observed, many studies reported that prior use of inhaled corticosteroids reduced CAP mortality in COPD patients 25 .
-Chronic cardiovascular disease increased the risk of CAP up to threefold 15 .
-Cerebrovascular disease/stroke and dementia approximately doubled the risk of CAP 26 .
-Diabetes mellitus was associated with a moderate increase in the risk of CAP 27 .
-Chronic liver or renal disease increased the risk of CAP approximately twofold 15 .
-Hospitalization in the previous five years was associated with an increased risk of CAP 16 .
-Immunosuppression: human-immunodeficiency virus (HIV) infection, asplenia 28 .
Genetic Factors
New studies have revealed that host genetic susceptibility is a risk factor for CAP. Some studies suggest that specific mutations or polymorphisms play an important role in the variable immune response to CAP. The innate immune system is crucial to host defences against pathogenic microorganism. Toll-like receptors (TLR) are proteins that recognize bacterial pathogens.
-Toll-like receptor 4 (TLR4) A299G polymorphism. The results of a recently published meta-analysis 29 suggest that susceptibility to pneumonia is associated with TLR4 A299G polymorphism.
-TLR6 polymorphism is associated with increased risk of Legionnaires' disease 30 .
Other risk factors
The use of proton pump inhibitors also has been reported as additional risk factor for CAP 31 . A recent systematic review and meta-analysis of the risk of CAP with outpatient proton pump inhibitor therapy found the risk of CAP increased 1.5-fold in outpatients using proton pump inhibitor therapy 32 .
CAUSATIVE PATHOGENS
Several studies on the microbial aetiology of CAP have been published in the past 15 years 6, 33 . Some of them showed that microbial causes of CAP differ according to the severity of disease at clinical presentation 34 (Table 1) .
Streptococcus pneumoniae (pneumococcus) remains the most frequent pathogen in CAP. However, its incidence is decreasingly reported due to several factors including the introduction of polysaccharide vaccine PCV7 and PCV13 and the decreased rate of smoking in countries such as the USA 35 . An estimated prevalence of 19.3-27.9% was reported for S. pneumoniae in Europe 36 . Furthermore, pneumococcus was observed less frequently in CAP cases treated in the community than in cases treated in the hospital or ICU. Intracellular pathogens (Mycoplasma pneumoniae, Legionella pneumoniae, Chlamydophila pneumonia, Chlamydophila psittaci and Coxiella burnetii), together with pneumococcus, are the most frequently reported pathogens causing CAP in both outpatients and hospitalized patients 33 .
A study by Arnold et al. 37 reported a 20% incidence of intracellular pathogens in CAP patients. Intracellular pathogens sometimes appear to cause more severe disease with respiratory failure and multisystem dysfunction associated with fatal outcomes. These microorganisms may cause severe CAP in approximately 1-7% of cases 33 .
Respiratory viruses are also a common cause of CAP and account for 7-36% of cases with defined microbial aetiology 6, 38 . The incidence of respiratory viruses varies with seasonality, geographic location, and age group. A good example of this is the recently published study by Jain et al. 6 on CAP in hospitalized adult patients, where the three principal pathogens reported in this study were rhinovirus (9%), influenza virus (6%), and S. pneumoniae (5%). It is known that seasonal influenza virus and respiratory syncytial virus cause pneumonia in very young and very old patients 39 . However, pandemic viruses affect mostly children and younger adults 40 . 43 and, more recently, MERS-CoV described in 2012 44 , community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) 45 , and H1N1 pandemic influenza virus in 2009 have also become CAP pathogens relatively recently.
Antibiotic-resistant pathogens are a worldwide concern. Approximately 6% of CAP cases are caused by multidrug-resistant (MDR) pathogens. (S. aureus and P. aeruginosa were most frequently isolated) 46 . In a European study of pathogens isolated from hospitalized patients with CAP, MDR pathogens were the cause of CAP in 3.3-7.6% of patients in whom a pathogen was identified, with methicillinresistant S. aureus being the most common MDR pathogen 47 . The study by Prina et al. 46 that analysed 1,519 patients with CAP who presented aetiological diagnosis, found that PES (Pseudomonas aeruginosa, Enterobacteriaceae extended spectrum b-lactamase-positive, and methicillin-resistant Staphylococcus aureus) pathogen was identified in 6% of the CAP cases. The study also found that PES pathogens are associated with increased risk of 30-day mortality (OR: 2.51; 95% CI: 1.20-5.25; p = 0.015). This study proposed a score to assess the risk of pneumonia due to PES pathogens (Table 2) .
Furthermore, S. pneumoniae, the most common cause of CAP, has increased its resistance to several antibiotics (cephalosporins, macrolides and fluoroquinolones) worldwide in the last two decades 48 . Currently, 20-30% of pneumococcus disease cases worldwide are MDR (resistant to more than three classes of antibiotics) (Fig. 4) .
However, mortality rates related to antibiotic-resistant S. pneumoniae have not increased due to interventions such as conjugated pneumococcal vaccine, which covers the serotypes that are most likely to express resistance 49 . A recent Spanish study 50 compared clinical outcomes in hospitalized patients with and without macrolide-resistant pneumococcus and reported no evidence suggesting that patients hospitalized for macrolide-resistant S. pneumoniae pneumonia were more severely ill on presentation or had worse clinical outcomes if they were treated with guideline-compliant versus noncompliant regimens.
Community acquired MRSA has become an important CAP pathogen. Community and hospital MRSA share a mecA gene that confers universal methicillin and β-lactam resistance, but CA-MRSA presents broader antibiotic susceptibility than hospital MRSA. CA-MRSA carries the gene for the Panton-Valentine leukocidin (PVL) toxin, which causes leukocyte destruction and tissue necrosis 51 . Pseudomonas aeruginosa is not a frequent pathogen in CAP 33 . However, several studies reported that More recently, the emergence of macrolide-resistant M. pneumoniae strains 54 , principally in Asian countries 55 , in some European countries 56 , and in the US 57 is becoming a global problem. However, the clinical significance of macrolide resistance of M. pneumoniae in CAP outcomes is still unknown.
RISK FACTORS ASSOCIATED WITH SPECIFIC PATHOGENS IN COMMUNITY-ACQUIRED PNEUMONIA
Several studies have identified specific risk factors for a number of pathogens in CAP cases (Table 3 ).
In the case of S. pneumoniae, the most frequent pathogen in CAP cases, one study recently described the risk factors for pneumonia due to fluoroquinolone-resistant S. pneumoniae as previous use of fluoroquinolones, current residence in a nursing home, nosocomial acquisition of pneumococcal infection, penicillin resistance, and COPD 58 . In the US, the SENTRY study reported that the rate of Risk factors for S. aureus include advanced age, underlying lung disease, and previous antibiotic use, whereas the two reported risk factors for methicillin-resistant S. aureus were prior hospitalization in the previous 90 days and requiring admission to the ICU 47 . Risk factors for CA-MRSA include a history of viral upper respiratory infection, smoking, recent hospitalization, and chronic pulmonary disease 62 . Recognized high-risk groups for CA-MRSA carriage and infection are athletes, military personnel, detainees in jail or prison, and children in day care centres 63 . Since, the household is a major community-acquired reservoir for CA-MRSA, spread beyond households established this pathogen in the communities 64 .
For P. aeruginosa, pulmonary comorbidity is the major risk factor. Recently, Cilloniz et al. 53 , in a cohort of 2,023 patients with CAP, reported that 4% of cases were caused by P. aeruginosa; risk factors related to this pathogen were male sex, chronic respiratory disease, C-reactive protein < 12.35 mg/dl, and PSI risk class IV-V. In the case of MDR P. aeruginosa CAP, the only risk factor was prior antibiotic treatment.
MICROBIOLOGICAL DIAGNOSIS
Initial antibiotic treatment of CAP is empiric in the majority of the cases. Determining the microbial aetiology of CAP is fundamental to ensuring appropriate antibiotic therapy, which is an important factor for reducing mortality 65 . However, in 50% of cases of CAP, the microbial aetiology is unknown 66 . International CAP guidelines 66, 67 recommend an optional microbiological diagnostic test in low-to-mild cases of CAP, which should be Microbiological diagnosis of CAP continues to be based on respiratory samples or blood culture. The main problems with these conventional methods are the low yield and long turnaround time (48-72 hours) and the fact that previous antibiotic use affects microbiological results 68 . However, the most important application of these methods is the ability to determine antibiotic susceptibility patterns that will allow for selection of appropriate antimicrobial therapy. -Severe obstructive lung disease: sputum culture.
-Pleural effusion: sputum and blood culture, urinary antigen test for pneumococcus and Legionella, pleural fluid culture.
-Cavitary infiltrates: sputum culture (bacteria, fungi and mycobacteria) and blood culture.
-Active alcoholism: sputum and blood culture, urinary antigen test for pneumococcus and Legionella.
-Severe CAP admitted to ICU: sputum and blood culture, urinary antigen test for pneumococcus and Legionella, tracheal aspirate or bronchoalveolar lavage culture; viral studies also are recommended in these patients.
-Epidemiological factors or specific risk factors suggesting pathogen: urinary antigen test for Legionella (Legionnaires' disease), influenza test during influenza season.
Biomarkers
Inflammatory biomarkers have been extensively investigated as a complementary prognostic tool for the management of CAP patients. They may be useful in the diagnosis, prognosis, and follow-up treatment of CAP patients, and they are also used for investigating antibiotic modifications 71 .
The most frequent biomarkers studied are C-reactive protein (CRP), procalcitonin (PCT), and cytokines interleukin (IL)-6 and tumour necrosis factor (TNF)-α 72 .
However, IL-6 and TNF-α are used for research purposes and are not routinely assessed in clinical practice.
Measurement of PCT gives information about the severity of the disease and may help physicians to differentiate typical bacterial aetiology from atypical aetiology. A study by Johansson et al. 73 showed that high PCT levels are related to invasive disease and pneumococcal aetiology. Higher levels of PCT are associated with bacterial pneumonia 74 . A recent study by de Jong et al. 75 on the efficacy and safety of PCT guidance in reducing the duration of antibiotic treatment in critically ill patients showed that PCT guidance encourages reduction of treatment duration and daily defined doses in critically ill patients with a presumed bacterial infection. This reduction was associated with a significant decrease in mortality in this population.
CRP was the pioneer biomarker and was discovered in the serum of patients with pneumococcal pneumonia. Appropriate antibiotic treatment and good outcomes have been demonstrated by decreasing levels of CRP after 3-4 days 76 .
Several studies showed that CRP value used together with disease severity scores such as PSI or CURB65 offered predictive severity accuracy in CAP 71, 77 .
The study by España et al. 78 on the utility of PCT and CRP in non-severe CAP patients showed that PCT with a cut-off point of 0.15 ng/ml was the best predictor for bacterial aetiology and for selecting patients eligible for outpatient care; levels of PCT and CRP positively correlate with increasing severity of CAP.
Pro-adrenomedullin (pro-ADM) showed a good correlation between levels of this biomarker and severity and short-term mortality in CAP studies. Several studies have suggested combining this biomarker with severity scores such as PSI and CURB-65 in order to improve the prediction of mortality and complications in CAP patients 79 .
D-dimer: a study by Shilon et al. 80 found a correlation between the levels of D-dimer and PSI risk class and hospital mortality in CAP patients. This study concluded that D-dimer levels at admission may predict the severity of CAP.
TREATMENT
Following a diagnosis of pneumonia, the clinician must decide the appropriate location for care and treatment: management in the community (outpatient), hospital admission, or ICU. Patients at low risk of complications are candidates for outpatient care, thus reducing inappropriate hospitalization and consequent inherent morbidity and costs 66, 67 . The use of severity assessment tools can facilitate decision-making and can also guide the clinician's choice of antibiotic therapy. Delays in determining the severity of the illness and where to treat the patient may have an impact on clinical outcome and hospital costs 1 .
ASSESSMENT OF SEVERITY AND MAKING SITE-OF-CARE DECISIONS
Scoring systems such as the Pneumonia Severity Index (PSI) and CURB-65 score predict short-term mortality and were developed specifically to make the decision to admit to hospital more objective 81, 82 . However, these two scores are subject to certain limitations: low sensitivity and specificity for predicting the requirement for ICU admission 83 ; the inappropriate weight given to the age variable in the PSI score, which could obscure younger patients with severe disease and vice versa (not valid in children); and neither score considers factors such as psychosocial factors, infrequent comorbidities, or patient preference regarding treatment 84 .
Recently, new severity score Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) 2007 criteria 66 have been developed to determine ICU admission. In 2007, IDSA/ATS proposed different major and minor criteria to identify patients with severe CAP requiring ICU admission. This is based on physiological variables; in particular, minor criteria are easy to use and show high specificity (91.7%) for predicting ICU admission and need for intensive respiratory or vasopressor support. Even in the absence of major criteria, the presence of at least three minor criteria is associated with complications and a high 30-day mortality risk.
More recently, Liu et al. 85 proposed a modified score called the expanded CURB-65, which adds three new variables to the CURB-65 score (lactic dehydrogenase > 230 µ/l, albumin < 3.5 g/dl, platelet count < 100 x 10 9 /l); this new score is a comparatively simpler and more effective marker in assessing the severity of hospitalized patients with CAP. The expanded CURB-65 score significantly improves identification of high-risk patients by decreasing the relative weight of age and blood pressure and eliminating the use of imaging and comorbid illnesses in the calculation.
CAP is associated with long-term mortality 86 . Several risk factors have been reported to be associated with long-term mortality for CAP, including age, cardiovascular disease, COPD, low serum albumin level at admission, diabetes, and dementia 87 . Recent studies have focused on the relationship between CAP and cardiovascular risk as it is now known that there is link with poor outcome in patients hospitalized for CAP and also with patients after discharge 88 . Approximately 10-30% of cardiovascular events occur in CAP patients and are related to short-term and long-term outcomes 89 .
INTERNATIONAL GUIDELINES RECOMMENDATION FOR ANTIMICROBIAL TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA
In general, the choice of empirical treatment is based on three main factors: CAP can be caused by many pathogens and no specific clinical presentation, laboratory data, or radiological features that distinguish each pathogen exist.
Microbiological diagnostic tests provide information hours or days after pneumonia presents. Delay in appropriate antibiotic therapy may be associated with significant mortality 90 .
A study by Menendez et al. 91 showed that the failure of physicians to adhere to guidelines is an independent risk factor for treatment failure and mortality in CAP cases. Tables 5,  6 , and 7 summarize the recommendations of the British Thoracic Society, ATS/IDSA, and European Respiratory Society/European Society of Clinical Microbiology and Infectious Diseases guidelines.
Adjuvant therapy
Because systemic corticosteroids have broadspectrum anti-inflammatory activity, they are Table 5 . Guidelines for the management and treatment of community-acquired pneumonia BTS guidelines 93 Outpatients/low severity • CURB65 score of 0 to 1.
• Empirical therapy is primarily directed at S. pneumoniae.
• Treat with oral amoxicillin (preferred agent, dose of 500 mg, three times daily), or doxycycline, or clarithromycin for patients hypersensitive to penicillin.
Inpatients moderate severity
• CURB65 score of 2.
• Treat with oral amoxicillin plus clarithromycin.
• When oral therapy is contraindicated, the preferred parenteral choices include intravenous amoxicillin or benzylpenicillin, together with clarithromycin.
• Alternative for patients intolerant to penicillins or macrolides: doxycycline, moxifloxacin, or levofloxacin. IV recommendations include levofloxacin monotherapy, a second generation (e.g. cefuroxime), or a third-generation (e.g. cefotaxime or ceftriaxone) cephalosporin together with clarithromycin.
Inpatients high severity
• CURB65 score of 3 to 5.
• Treat immediately after diagnosis.
• Treat with an intravenous combination of a broad-spectrum β-lactamase stable antibiotic such as co-amoxiclav, together with a macrolide, such as clarithromycin is preferred.
• In patients allergic to penicillin, a second-generation (e.g. cefuroxime) or third-generation (e.g. cefotaxime or ceftriaxone) cephalosporin can be used instead of co-amoxiclav, together with clarithromycin.
• Patients with Pseudomonas infection: ceftazidime plus gentamicin or tobramycin (dose monitored). Alternatively, ciprofloxacin or piperacillin, plus gentamicin or tobramycin (dose monitored).
used as adjunctive therapy for CAP and several studies reported their association with a short time to clinical stability, an earlier switch to oral sequence therapy, shorter length of hospital stay, less treatment failure, and lower mortality in patients with severe CAP. However, some studies suggested that systemic corticosteroids in patients with influenza Outpatients/low severity • PSI OR CURB65 score to guide outpatient treatment.
Treat previously healthy patients with low risk of drug-resistant pneumococci with a macrolide (azithromycin, clarithromycin, or erythromycin) (strong recommendation; level I evidence) or doxycycline (weak recommendation; level III evidence).
• Treat patients with a high risk of drug-resistant pneumococci with a fluoroquinolone or β-lactam plus macrolide. Presence of comorbidities, use of immunosuppressing drugs, use of antimicrobials within the previous 3 months, or other risks of DRSP infection:
• Treat with respiratory fluoroquinolone (moxifloxacin or levofloxacin [750 mg]) (strong recommendation; level I evidence).
• β-lactam plus a macrolide (high-dose amoxicillin [e.g. 1 g three times daily] or amoxicillin-clavulanate [2 g twice daily] is preferred; alternatives include ceftriaxone, cefpodoxime, and cefuroxime [500 mg, twice daily]; doxycycline [level II evidence] is an alternative to the macrolide) (strong recommendation; level I evidence). In regions with a high rate (> 25%) of infection with high-level (MIC ≥ 16 mg/ml) macrolide-resistant Streptococcus pneumoniae:
• Consider the use of alternative agents listed above for any patient, including those without comorbidities (moderate recommendation; level III evidence).
Patients directly admitted to hospital:
• Treat with a respiratory fluoroquinolone (strong recommendation; level I evidence) or a β-lactam plus a macrolide (strong recommendation; level I evidence).
• Preferred β-lactam agents include cefotaxime, ceftriaxone, and ampicillin; ertapenem for selected patients; with doxycycline (level III evidence)
as an alternative to the macrolide.
• A respiratory fluoroquinolone should be used for penicillin-allergic patients.
Patients who require ICU admission:
• Treat with β-lactam (e.g. cefotaxime, ceftriaxone, or ampicillin-sulbactam) plus either azithromycin (level II evidence) or a fluoroquinolone (level I evidence) (strong recommendation).
• Alternatively, a respiratory fluoroquinolone and aztreonam are recommended for penicillin-allergic patients.
Patients with Pseudomonas infection:
• Treat with either an antipneumococcal, antipseudomonal β-lactam (e.g. piperacillin-tazobactam, cefepime, imipenem, or meropenem) plus either ciprofloxacin or levofloxacin (750 mg dose is recommended), or the above β-lactam plus an aminoglycoside and azithromycin, or the above β-lactam plus an aminoglycoside and an antipneumococcal fluoroquinolone.
• For patients allergic to penicillin, the above β-lactam should be substituted with aztreonam (moderate recommendation; level III evidence).
Patients with community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infection:
Add vancomycin or linezolid to standard CAP therapy (moderate recommendation; level III evidence). pneumonia are associated with increased mortality 92 . Future studies are needed in order to determine in which cases corticosteroid therapy should be recommended.
Statin therapy is used as adjunctive therapy for CAP as some studies have shown them to have anti-inflammatory and antioxidative effects and ability to reduce cardiovascular events 93 . Macrolides are used as adjunctive therapy for CAP because of their several immunomodulatory effects, and because they can attenuate the virulence factors of some important bacteria, such as S. pneumoniae, where they inhibit pneumolysin production; they also inhibit the quorum sensing by bacteria 94 .
Prevention
International guidelines 66, 67 recommend specific measures to prevent pneumonia. The most important of these is the use of pneumococcal vaccines (polysaccharide and conjugated) and influenza vaccines in all older adults and for younger persons with medical conditions that place them at high risk for pneumonia morbidity and mortality. Annual influenza vaccination is also recommended in healthcare workers, inpatient and outpatient settings, and long-term care facilities.
Since the risk of CAP is increased in current smokers 12 , the general recommendation is to offer smoking cessation in these patients.
Pneumococcal vaccination
Vaccination remains the primary strategy for the prevention of CAP, especially in an at-risk population (young children, the elderly, patients with comorbidities, and the immunocompromised). Two types of vaccine are currently available: polyvalent pneumococcal polysaccharide vaccine (PPV) and the pneumococcal conjugate vaccines (PCV). The main difference between the types of vaccine is that PPV contains amounts (25 µg) of unconjugated purified capsular polysaccharides of each of the 23 pneumococcal serotypes, whereas in PCV, the capsular polysaccharides (2-4 µg depending on the antigen) are conjugated to a carrier protein to enhance immunogenicity 95 . Because of the limitation of PPV23 in children, a new conjugated vaccine was developed.
Several studies assessed the effectiveness of PPV23 in CAP in the elderly 96, 97 -Previously vaccinated with PPV23: one dose of PCV13 (≥ 1 year after receipt of most recent PPSV23 dose) followed by one dose of PPV23 (≥ 8 weeks following dose of PCV13, and ≥ 5 years since most recent dose of PPV23).
EUROPEAN CONSIDERATION FOR PCV13 VACCINATION
In March 2015, the European Commission approved and issued indications for PCV13 (PCV13 Summary of Product Characteristics, July 2015):
-PCV13 is indicated for active immunization for the prevention of IPD, pneumonia, and acute otitis media in infants, children, and adolescents from 6 weeks to 17 years of age;
-It is also indicated for active immunization for the prevention of IPD and pneumonia in adults ≥ 18 years of age, and the elderly.
ON-GOING STUDIES OF NEW TREATMENTS IN COMMUNITY-ACQUIRED PNEUMONIA
Several new antibiotics are in clinical development, with promising results for treating CAP.
Ceftaroline fosamil
Ceftaroline fosamil is a fifth-generation, parenteral, extended-spectrum cephalosporin that binds to penicillin-binding proteins and prevents synthesis of the bacterial cell wall. 
Ceftobiprole
Ceftobiprole is a broad-spectrum parenteral cephalosporin and has microbiological activity against most typical bacterial pathogens that cause CAP, including MRSA 105 .
Nemonoxacin
Nemonoxacin is a non-fluorinated, broad-spectrum quinolone. Nemonoxacin displayed greater activity than the fluoroquinolones (levofloxacin) against methicillin-sensitive S. aureus, methicillin-sensitive Staphylococcus epidermidis (MSSE), methicillin-resistant S. epidermidis (MRSE), S. pneumoniae, and Enterobacter faecalis. Interestingly, nemonoxacin maintained better activity against community-acquired MRSA than against hospital-acquired MRSA 106 
Solithromycin
Solithromycin is a novel fluoroketolide with high potency against gram-positive and gramnegative bacteria commonly associated with CAP and skin structure infections 107 .
Cethromycin
Cethromycin is a new fluoroketolide with a reported high potency against gram-positive and gram-negative bacteria, and atypical pathogens (including mycoplasma and ureaplasma). It also has in vitro activity against penicillin-resistant and macrolide-resistant grampositive organisms, possibly due to a high affinity for the target site on the ribosomal unit 108 .
CONCLUSIONS
Community-acquired pneumonia remains a significant cause of morbidity and mortality worldwide despite the improved management of CAP patients. In the past 15 years, several population-based data studies on the epidemiology and microbial aetiology of CAP have been published, showing that S. pneumoniae (pneumococcus) is still the most frequent pathogen in CAP in all settings, in all age groups, and regardless of comorbidity. Respiratory viruses, especially influenza virus A and B, respiratory syncytial virus, and rhinovirus, are major causes of CAP. Despite the development of new molecular techniques and the implementation of diagnostic tests in CAP, more than 50% of cases remain without microbiological diagnosis. A major problem is the increased rate of antibiotic resistance of frequent pathogens in CAP and the emergence of MDR pathogens.
